| Literature DB >> 33377122 |
Nils Rother1, Cansu Yanginlar1, Rik G H Lindeboom2, Siroon Bekkering3, Mandy M T van Leent4,5, Baranca Buijsers1, Inge Jonkman1, Mark de Graaf1, Marijke Baltissen2, Lieke A Lamers2, Niels P Riksen3, Zahi A Fayad4, Willem J M Mulder4,6,7, Luuk B Hilbrands1, Leo A B Joosten3, Mihai G Netea3,8, Michiel Vermeulen2, Johan van der Vlag1, Raphaël Duivenvoorden1,4.
Abstract
Hydroxychloroquine is being investigated for a potential prophylactic effect in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but its mechanism of action is poorly understood. Circulating leukocytes from the blood of coronavirus disease 2019 (COVID-19) patients show increased responses to Toll-like receptor ligands, suggestive of trained immunity. By analyzing interferon responses of peripheral blood mononuclear cells from healthy donors conditioned with heat-killed Candida, trained innate immunity can be modeled in vitro. In this model, hydroxychloroquine inhibits the responsiveness of these innate immune cells to virus-like stimuli and interferons. This is associated with a suppression of histone 3 lysine 27 acetylation and histone 3 lysine 4 trimethylation of inflammation-related genes, changes in the cellular lipidome, and decreased expression of interferon-stimulated genes. Our findings indicate that hydroxychloroquine inhibits trained immunity in vitro, which may not be beneficial for the antiviral innate immune response to SARS-CoV-2 infection in patients.Entities:
Keywords: COVID-19; SARS-CoV-2; chloroquine; hydroxychloroquine; innate immune memory; interferon; lipidome; monocytes; trained immunity
Mesh:
Substances:
Year: 2020 PMID: 33377122 PMCID: PMC7762774 DOI: 10.1016/j.xcrm.2020.100146
Source DB: PubMed Journal: Cell Rep Med ISSN: 2666-3791